Fragment-based Drug Discovery Market By Service Type (Fragment Screening Technique, Fragment Optimization Technique), By End-User (Biopharmaceutical Companies, Contract Research Organization, Academic And Research Institutions) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

The global fragment-based drug discovery (FDD) market held US$ 503.4 Mn in 2017 and expected to grow at compound annual growth rate (CAGR) of 11.8% during the forecast period from 2018 to 2026. Fragment-based drug discovery has emerged as a significant substitute to high throughput screening (HTS) in last two decades for the identification of lead compounds for drug discovery. Introduction of novel techniques in existing fragment-based drug discovery process has reduced time and cost of production which has led to the growing demand of fragment-based drug design. In comparison to HTS, fragment-based approach requires screening of fewer compounds and offers more efficient and productive optimization of compounds. 

Growing uptake of FBDD by biopharmaceutical companies with an aim of cost effectiveness and high productivity is projected to drive the fragment-based drug discovery market. Moreover, employment of fragment-based drug discovery has created demand for specialized and efficient biophysical techniques that are capable weak affinity interactions. These include nuclear magnetic resonance (NMR) spectroscopy, x-ray crystallography, and capillary electrophoresis among others. Technological advancements in these screening technologies will further drive the growth of the market. North America dominated the global fragment-based drug discovery market owing to high R&D by biopharmaceutical companies for time and cost-efficient drug discovery techniques. Asia Pacific is projected to grow at fastest growth rate during the forecast period due to number of CROs operating in the region and growing outsourcing of pharmaceutical manufacturing in Asia Pacific. 

"Technological advancements to drive the Fragment-based Drug Discovery Market"

In 2017, NMR spectroscopy and x-ray crystallography are the leading segments in the global fragment-based drug discovery market. NMR spectroscopy is highly productive and efficient due to recent modifications and most commonly used technique. Companies such as Abbott Laboratories, Novartis, and Roche are reported to be using NMR spectroscopy for fragment-based drug discovery. X-ray crystallography provides a detailed profile of fragment-binding and identifying crystal structures has become a high-throughput process with the help of x-ray crystallography. Moreover, x-ray crystallography is considered gold standard in orthogonal fragment screening as it confirms the binding of the protein to the target. Other techniques that are extensively used for fragment-based drug discovery is capillary electrophoresis, surface plasmon resonance, mass spectroscopy and differential scanning fluorimetry; expected to witness substantial growth during the forecast period thereby driving the fragment-based drug discovery market.

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Fragment-based Drug Discovery market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on service type, end-user, and geography.

Market is studied in order to understand the current dynamics and future trends in the global fragment-based drug discovery market. The study includes market size and forecast for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rate (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year. The key players currently engaged in fragment-based drug discovery market include Astex Pharmaceuticals, Charles River Laboratories International, Inc., Evotec AG, Kinetic Discovery Limited, Alveus Pharmaceuticals Pvt. Ltd. Among others.